A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy
About the study
The purpose of this study is to determine whether CVL-871 is safe and tolerable in patients with Dementia-Related Apathy and if CVL-871 shows changes in clinical measurements of apathy.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Meets diagnostic criteria for apathy in neurocognitive disorders
- Clinically significant apathy
- Mild to Moderate Dementia (AD, FTD, VAD, or DLB)
EXCLUSION CRITERIA
Exclusion Criteria:
- Other significant psychiatric disorder(s)
- Other neurological disorders (other than AD, FTD, VAD, or DLB)
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Apathy in Dementia
Age (in years)
50 - 85
Phase
Phase 2
Participants needed
75
Est. Completion Date
Oct 31, 2024
Treatment type
Interventional
Sponsor
Cerevel Therapeutics, LLC
ClinicalTrials.gov identifier
NCT04958031
Study number
CVL-871-2001
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?